logo
#

Latest news with #PrashanthTapse

Anthem Biosciences lists at 27% premium; should you book profit or hold?
Anthem Biosciences lists at 27% premium; should you book profit or hold?

Business Standard

time18 hours ago

  • Business
  • Business Standard

Anthem Biosciences lists at 27% premium; should you book profit or hold?

Anthem Biosciences IPO listing, Anthem Biosciences share price: Shares of innovation-driven and technology-focused company Anthem Biosciences made a solid D-Street debut on Monday, July 21, following the completion of its initial public offering (IPO). The company's shares listed at ₹723.10 per share on the BSE, reflecting a premium of ₹153.10 or 26.86 per cent over the issue price of ₹570 per share. On the National Stock Exchange (NSE), Anthem Biosciences shares listed at a mildly lower premium of ₹153.05 or 26.85 per cent at ₹723.05 per share over the issue price. Anthem Biosciences IPO listing came below the grey market estimate. Ahead of their debut on the bourses, the unlisted shares of Anthem Biosciences were exchanging hands at around ₹749 per share, reflecting a grey market premium (GMP) of ₹179 per share or nearly 31.40 per cent over the issue price of ₹570 per share, showed the sources that track unofficial market activities. Should you book profit or hold? The listing of the company's shares, Prashanth Tapse, senior VP (research), Mehta Equities, said was broadly in line with expectations. While post-listing valuations may appear premium, Tapse believes these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility. "The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation," said Tapse, and recommended investors to 'hold' Anthem Biosciences for a long-term perspective. "For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. Short term, we foresee ₹900 as a target, while long-term investors can hold it for ₹1,000 and above. Non-allottees should wait for some volatility to settle in price, and in any case, if the stock is available around ₹650–680, it can be considered a good range to accumulate with a long-term vision," said Tapse. Shivani Nyati, head of wealth at Swastika Investmart, on the other hand, recommended investors to secure partial profits. "The company is one of the leading global players in the CRDMO segment and enjoys a niche position, leading the pack of players. The company has shown steady growth in its top line during the reported periods," said Nyati. She further recommended the investors to retain the remaining stake with a stop-loss set at ₹650. Anthem Biosciences IPO details Anthem Biosciences IPO comprised entirely an offer-for-sale (OFS) with promoters and shareholders divesting up to 59.6 million equity shares estimated to be worth ₹3,395 crore. The public issue was offered at a price band of ₹540–570 with a lot size of 26 shares, and was open for subscription from July 14, 2025, till July 16, 2025. Anthem Biosciences received strong demand from investors for its public issue as it got oversubscribed by 63.86 times. The demand was led by the qualified institutional buyers (QIBs), who bid for 182.65 times the category reserved for them, showed the NSE data. Anthem Biosciences, as outlined in its red herring prospectus (RHP), will not use any proceeds from the public issue, and it will be given to the promoters and shareholders selling their stakes through the OFS. About Anthem Biosciences Incorporated in 2006, Anthem Biosciences is a contract research, development, and manufacturing organisation (CRDMO) serving global customers. The company manufactures specialised fermentation-based APIs, including probiotics and enzymes. Anthem Biosciences has a diverse customer base, including biotech firms and large pharmaceutical companies, spanning over 44 countries. As of September 2024, the company had 196 projects and over 425 customers in its CRDMO business. The company holds one patent in India and seven overseas, with 24 pending global patent applications.

Anthem Biosciences soars on debut: Shares jumps 3% after healthy listing - Should you buy now?
Anthem Biosciences soars on debut: Shares jumps 3% after healthy listing - Should you buy now?

Time of India

time18 hours ago

  • Business
  • Time of India

Anthem Biosciences soars on debut: Shares jumps 3% after healthy listing - Should you buy now?

Anthem Biosciences shares surged 3.3% to Rs 746.70 during Monday's intraday trading session on BSE, after making a strong debut with a 27% premium over its IPO price. The company's IPO investors are now sitting on overall gains of around 31%, ET reported. The stock market welcomed Anthem Biosciences with a robust listing premium of 26.84%, opening at Rs 723 compared to its issue price of Rs 570. The IPO received an extraordinary response with 67.42 times subscription across investor categories. The offering consisted entirely of an offer for sale, with proceeds directed to existing shareholders. Prior to the public offering, anchor investors contributed Rs 1,016 crore. Should you buy the shares now? Prashanth Tapse, Senior VP (Research) at Mehta Equities, told ET that, "While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility." Based on the company's financial performance and industry position, he further advised investors to "HOLD" Anthem Biosciences with a long-term outlook. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Fastest Selling Plots of Mysore from 40L | 40+ Amenities PurpleBrick Learn More Undo "For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, which justifies the listing," he noted. The analysis suggests a short-term target of Rs 900, whilst long-term investors might consider holding for Rs 1,000 and beyond. For those who missed the IPO allocation, it's advisable to wait for price stabilisation, ET reported. Established in 2006, Anthem's operations span across drug discovery, development, and commercial manufacturing for both small molecules and biologics. The company's FY25 financial performance showed revenue growth of 30% to Rs 1,930 crore and profit increase of 23% to Rs 451 crore. EBITDA stood at Rs 684 crore with a 37% margin, maintaining minimal debt levels. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now

HDFC Bank stock climbs over 2 pc post earnings announcement
HDFC Bank stock climbs over 2 pc post earnings announcement

News18

timea day ago

  • Business
  • News18

HDFC Bank stock climbs over 2 pc post earnings announcement

Agency: PTI New Delhi, Jul 21 (PTI) Shares of HDFC Bank went up by over 2 per cent on Monday after the company reported a steady set of quarterly numbers. The heavyweight stock advanced 2.27 per cent to Rs 2,001.90 on both the BSE and NSE. 'HDFC Bank reported a steady set of numbers," VK Vijayakumar, Chief Investment Strategist, Geojit Investments Ltd, said. HDFC Bank on Saturday posted a 1.31 per cent decline in its consolidated net profit to Rs 16,258 crore for the June 2025 quarter. The lender had reported a net profit of Rs 16,475 crore in the year-ago period. On a standalone basis, the country's largest private sector lender reported a net profit of Rs 18,155 crore for the quarter, up from Rs 16,174 crore a year ago. 'HDFC Bank posted 12 per cent year-on-year profit growth and announced a 1:1 bonus issue," Prashanth Tapse, Senior VP (Research), Mehta Equities Ltd, said. Rally in the stock drove the equity markets higher. The 30-share BSE Sensex traded 323.61 points higher at 82,081.34, and the NSE Nifty quoted 91.65 points up at 25,059.70. The core net interest income growth moderated to 5 per cent to Rs 31,400 crore during the quarter, as the net interest margin narrowed to 3.35 per cent, from 3.46 per cent in the quarter-ago period amid a 6.7 per cent growth in gross advances. The gross non-performing assets ratio inched up to 1.4 per cent as of June 30, from 1.33 per cent three months ago, largely because of cyclical reverses in the agricultural portfolio. PTI SUM DRR view comments First Published: July 21, 2025, 11:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Closing bell! Enviro Infra to Tata Motors- Prashanth Tapse of Mehta Equities suggests stocks to buy in the short term
Closing bell! Enviro Infra to Tata Motors- Prashanth Tapse of Mehta Equities suggests stocks to buy in the short term

Mint

time4 days ago

  • Business
  • Mint

Closing bell! Enviro Infra to Tata Motors- Prashanth Tapse of Mehta Equities suggests stocks to buy in the short term

Stock market today: The benchmark indices Sensex and Nifty experienced a significant decline on Friday due to foreign fund withdrawals and a lackluster beginning to the quarterly earnings season, which negatively affected investors' mood. Analysts noted that the sentiment surrounding banking stocks is particularly cautious following Axis Bank's recent financial results, which did not meet market expectations. The 30-share Sensex plummeted by 651.11 points or 0.79% to reach 81,608.13 during the trading day. Similarly, the 50-share Nifty 50 fell by 192.8 points or 0.76% to settle at 24,918.65. Prashanth Tapse from Mehta Equities suggests that if the Nifty 50 remains below 25,000, it may swiftly drop to 24,800 or even lower, making risk management crucial in the current circumstances. Tapse recommends these three stocks to buy in the near-term. Here's what he says about the overall market. Nifty 50 has fallen below the important 25,000 mark, showing that the market is turning more negative. This break suggests that the index may move down further, with the next support at 24,800. The failure to stay above 25,000 means sellers are still in control, possibly due to both global and local worries. Technical signals like RSI show weakness. Traders with short positions should keep a strict stop-loss at 25,100. If Nifty 50 stays under 25,000, it could quickly fall to 24,800 or lower, so managing risk is very important in these conditions. Bank Nifty has slipped below its key support of 56,600, making banking stocks more vulnerable. The index could drop further to 56,000 or even 55,500, with 55,000 as a major support if selling continues. Technical indicators show a negative trend, and many private and PSU banks are under pressure. The short-term view is weak, so traders should keep a stop-loss at 57,000 on their shorts. Unless Bank Nifty moves back above 56,600, more declines are possible. It's best to wait for clear signs of recovery before buying aggressively. Prashanth Tapse recommends buying these three stocks in the short term - Enviro Infra, Tata Motors, and Astral. Buy at: ₹ 299 | Stop Loss: ₹ 294 | Target: ₹ 325, ₹ 330 Enviro Infra share price is starting to recover after a recent fall. The stock is close to strong support at ₹ 294, giving a good entry point with low risk. Technical indicators point to a possible move up towards ₹ 325 and ₹ 330. Traders can consider buying at the current price, but must keep a stop-loss at ₹ 294. Rising volumes will add confidence to the bullish view. If the stock closes below ₹ 294, the positive outlook will not hold, so following the stop-loss is important. Buy at: ₹ 684 | Stop Loss: ₹ 650 | Target: ₹ 750 Tata Motors share price looks attractive after falling back to ₹ 684. The stock is holding above key averages and may bounce back to ₹ 750. Technical charts, including RSI, show signs of a possible recovery. Traders should set a stop-loss at ₹ 650 to control risk. If the price goes above ₹ 700 and stays there, it will be a stronger buy signal. Weakness can be used to buy more, but if it falls below ₹ 650, positions should be exited. Buy at: ₹ 1,507 | Stop Loss: ₹ 1,450 | Target: ₹ 1,650, ₹ 1,700 Astral share price is moving sideways near support at ₹ 1,507 and could bounce back from here. The overall trend is still positive, with targets at ₹ 1,650 and ₹ 1,700 if buying picks up. Short-term technical indicators are showing some stability. Buy at current levels with a stop-loss at ₹ 1,450 to protect downside. If the price breaks above ₹ 1,530, it will confirm the bullish view. As long as the stop-loss is respected, the chances for higher levels remain good. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.

Benchmark indices slip into red amid selling in IT shares
Benchmark indices slip into red amid selling in IT shares

Hans India

time4 days ago

  • Business
  • Hans India

Benchmark indices slip into red amid selling in IT shares

Mumbai: Benchmark stock indices Sensex and Nifty settled lower on Thursday following selling in IT and banking shares and investors remaining in a wait-and-watch mode ahead of the outcome of the US-India trade talks. The 30-share BSE Sensex dropped 375.24 points or 0.45 per cent to settle at 82,259.24. During the day, it fell by 415.21 points or 0.50 per cent to 82,219.27. The 50-share NSE Nifty closed lower by 100.60 points or 0.40 per cent to 25,111.45. Fresh foreign fund outflows and subdued quarterly earnings dented investors' sentiment, experts said. Among Sensex firms, Tech Mahindra declined nearly 3 per cent after its June quarter earnings failed to cheer investors. IT services firm Tech Mahindra reported a nearly 34 per cent year-on-year increase in consolidated net profit to Rs 1,140.6 crore for the quarter ending June 30, 2025, on the back of growth in communications and financial services verticals. Infosys, HCL Tech, Eternal, Larsen & Toubro, Tata Consultancy Services and Axis Bank were also among the laggards. However, Tata Steel, Trent, Titan and Tata Motors were among the gainers. Foreign Institutional Investors (FIIs) offloaded equities worth Rs 1,858.15 crore on Wednesday, according to exchange data. 'Indian equity benchmarks ended marginally lower as investors exercised caution amid subdued Q1 earnings announcements, particularly in the technology and banking sectors. Market participants remained sidelined due to elevated valuations of large-cap stocks and FII outflows owing to the uncertainty regarding US-India trade deal; however, any positive developments could amplify market sentiment,' Vinod Nair, Head of Research, Geojit Investments Limited, said. The BSE smallcap gauge climbed 0.30 per cent and midcap index went up by 0.07 per cent. Among BSE sectoral indices, BSE Focused IT tanked 1.47 per cent, followed by IT (1.33 per cent), teck (1.06 per cent), bankex (0.51 per cent) and utilities (0.25 per cent). Realty jumped 1.22 per cent, metal climbed 0.62 per cent, commodities (0.42 per cent), healthcare (0.28 per cent) and consumer discretionary (0.25 per cent). 'Markets largely remained in the negative zone amid uncertainty over the impending announcement of the India-US tariff outcome, as investors resorted to selling in banking, IT and oil & gas shares that led the downfall in key benchmarks. Once the deal is announced and if it suits the interests of both the countries, there will be a relief in the markets and we may see short-term spurt, else the sluggish to pessimist mood could continue. 'Also, the ongoing earnings season will have a bearing on the markets, and investors would take positions based on how the results pan out going ahead,' Prashanth Tapse, Senior VP (Research), Mehta Equities Ltd, said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store